Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
  
  • Email Email
  • Comments Comments
  •  (3)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Fourth Generation HIV Diagnostic Test Approved, Permitting Earlier Detection of Infection

June 18, 2010

On June 18, 2010, FDA approved a new, "4th generation" HIV diagnostic assay. The ARCHITECT HIV Ag/Ab Combo Assay is the first HIV diagnostic assay that simultaneously detects both antigen and antibodies for the Human Immunodeficiency Virus (HIV). The new test is also the first diagnostic test approved by FDA for use in children as young as 2 years of age, and pregnant women.

Advertisement

This single, automated test, known as the ARCHITECT HIV Ag/Ab Combo Assay, is a highly sensitive chemiluminescent microparticle immunoassay intended to be used as an aid in the diagnosis of HIV-1/HIV-2 infection, including acute or primary HIV-1 infection. It is specific for the detection of the HIV-1 p24 antigen (the substance found on the virus that triggers the production of antibodies), as well as antibodies to HIV-1 groups M and O, and as antibodies to HIV-2.

Levels of p24 antigen increase early after initial infection, before HIV antibody is produced. Because it detects HIV-1 p24 antigen, in addition to antibodies, the ARCHITECT HIV Ag/Ab Combo Assay can be useful in extending diagnosis to earlier, acute phase (recent) infection with HIV, prior to the emergence of antibodies produced by the infected patient, effectively reducing the window period (that period after initial infection and before the detection of infection based on formation of detectable antibodies). The median detection time was demonstrated to be 7 days earlier (range 0 to 20 days) compared to 3rd generation enzyme immunoassay antibody tests to which they were compared.

Currently, most tests used in the diagnostic setting detect only HIV antibodies.

While the assay is not intended to be used for routine screening of blood donors, it is approved as a donor screening assay for HIV-1/HIV-2 infection in urgent situations where licensed blood donor screening tests are unavailable or their use is impractical.

Approximately 18 million persons in the United States are tested for HIV each year, and an estimated one million people are living with HIV. In 2008, CDC estimated that approximately 56,000 people are newly infected with HIV each year. This new test can help diagnose on-going and more recent infection, helping make people aware of their HIV status, get treatment, and help to reduce the spread of HIV by people unaware of their serostatus.

The ARCHITECT HIV Ag/Ab Combo Assay is manufactured by Abbott Laboratories, Abbott Park, Illinois.



  
  • Email Email
  • Comments Comments
  •  (3)
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by U.S. Food and Drug Administration. Visit the FDA's website to find out more about their activities and publications.
 
See Also
Quiz: Are You at Risk for HIV?
10 Common Fears About HIV Transmission
More on HIV Testing

 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement